The Core Components of a GTM Strategy
A go-to-market strategy for an early-stage AI product has five components. The ideal customer profile (ICP) defines exactly who you are selling to: company size, industry, role of the buyer, role of the user, and the specific situation that makes them a good fit for your product now. The value proposition defines what your product does for that ICP and why it is better than the alternative (which is often not a competing product but the current manual process). The channels define how you will reach that ICP: outbound sales, content marketing, product-led growth, partnerships, or paid acquisition. The pricing model defines how you will capture value: seat-based subscription, usage-based, outcome-based, or enterprise contract. And the sequencing plan defines in what order you will pursue different segments and channels, starting with the path most likely to generate early revenue and validated learning. Many founders treat these as parallel workstreams. They are better thought of as a sequential decision tree: the ICP choice constrains the channel choice, which constrains the pricing model, which constrains the sales motion.
Defining Your ICP for AI Products
AI products have a specific ICP challenge: the technical sophistication of the buyer matters more than in traditional software. Early adopters of AI products tend to be more technically sophisticated than later adopters, which means the ICP that will buy in month one may be different from the ICP you eventually want to serve at scale. Starting with technically sophisticated buyers who understand LLM limitations and can evaluate AI output quality critically generates better early feedback than targeting less sophisticated buyers who may misinterpret AI failures as product failures. For B2B AI products, the ICP also has a buying-side complexity: the user is often not the buyer. A legal AI product might be used by associates but purchased by the IT or innovation team or the managing partner. The GTM strategy must address both the user journey and the buyer journey. For UK products targeting regulated sectors, the compliance requirements of the ICP are part of the profile: NHS trusts have different procurement processes than private clinics, and FCA-regulated firms have data governance requirements that affect how they can adopt AI tools.
Channel Selection for AI SaaS Products
Channel selection is the most consequential GTM decision for early-stage products because it determines where you spend your time and money before you have validated what works. For B2B AI SaaS products with average contract values above GBP 5,000 per year, outbound sales, founder-led selling, and warm introductions through investor networks and advisors are the most efficient early channels. Content marketing and SEO take time to build and are better investments at stage two once you understand your ICP deeply. For B2B products with lower average contract values (GBP 500-5,000 per year), product-led growth approaches, free tiers, and self-serve onboarding are more efficient because the economics do not support a high-touch sales process. For B2C AI products, paid acquisition can work if the unit economics are positive, but the CAC payback period must be positive before scaling spend. Partnership channels, where your AI product integrates with a platform your ICP already uses, can be highly effective for reaching a concentrated ICP with lower CAC than direct acquisition.
Pricing Models for AI Products
AI products have pricing model options that traditional software does not, because the cost structure includes variable API costs that scale with usage. The main models to consider are subscription pricing, where customers pay a fixed amount per month or year regardless of usage; usage-based pricing, where customers pay per API call, per document processed, per query, or per output generated; outcome-based pricing, where customers pay based on measurable business outcomes such as cost savings or revenue generated; and hybrid pricing, where a base subscription covers a usage allowance with overage pricing above the limit. Subscription pricing is simpler to administer and produce predictable revenue, but leaves money on the table from high-usage customers and creates difficulty at low price points where API costs may approach revenue. Usage-based pricing aligns cost and value but creates unpredictable revenue for early-stage businesses. For UK products, any pricing model that involves recurring payments requires consideration of the Consumer Credit Act and Consumer Duty for consumer-facing products, and ICO requirements around transparent billing for subscription services.
GTM Sequencing: From Zero to Traction
The sequencing of GTM efforts in the first 12 months is as important as the choice of channel and ICP. Most successful B2B AI startups follow a recognisable pattern. Months 1-3: founder-led sales to a small number of initial customers found through personal networks, investor connections, or direct outreach to known ideal customers. The goal is not scale, it is learning: who buys, what they say about the problem, how they use the product, and what they are willing to pay. Months 3-6: with two to four paying customers, a repeatable sales motion starts to emerge. Messaging is refined based on what actually resonates. The ICP may be narrowed based on which customers activated and retained versus which churned. Months 6-12: with a defined ICP and proven messaging, investment in scalable channels, content, partnerships, or a first sales hire, begins to make sense. The specific timeline varies by product and market, but the principle of learning before scaling is consistent across successful AI SaaS GTM journeys.
GTM and Regulatory Compliance in the UK
For UK AI products, GTM strategy must account for regulatory constraints that affect when and how you can sell. FCA-regulated products cannot be sold to UK retail customers without authorisation or through an appointed representative arrangement. NHS procurement has specific pathways for digital health products that determine which sales motion is appropriate. The Digital Technology Assessment Criteria (DTAC) from NHS England is relevant for AI health products. ICO registration is required before collecting any personal data from UK customers, and the GDPR-required privacy notice must be in place before GTM activity that generates data processing begins. EU AI Act compliance documentation may be required before selling to enterprise customers in the EU, particularly in regulated sectors where buyers conduct technical due diligence. Building these requirements into GTM planning rather than discovering them as blockers during active selling saves significant time and reputational risk.